Navigation Links
Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
Date:8/5/2009

tigator, Thomas J. Louie, M.D., presented top-line data from Optimer's fidaxomicin North American Phase 3 clinical study for patients with Clostridium difficile infection at the European Congress of Clinical Microbiology and Infectious Diseases meeting, which showed the trial met its primary endpoint of achieving clinical cure compared to Vancocin(R). In addition, the top-line data showed that patients treated with fidaxomicin experienced a reduction in CDI recurrence compared to Vancocin (p=0.004) and had a higher global cure (cure with no recurrence within four weeks) compared to Vancocin (p=0.006).
  • Clinical investigator, Mark A. Miller, M.D., presented additional data from Optimer's fidaxomicin North American Phase 3 clinical study at the Digestive Disease Week 2009 Conference focusing on patient risk factors believed to be predictive of CDI recurrence following treatment. These risk factors include albumin levels, white blood cell (WBC) count and temperature and strain types of CDI. The data showed that fidaxomicin overall demonstrated a lower recurrence rate compared to Vancocin (p=0.004) regardless of albumin levels, WBC count and temperature, as well as for patients with non-BI (NAP1/027) strains.
  • The United States Patent and Trademark Office issued Optimer a production patent covering steps used in the manufacture of fidaxomicin.
  • About Optimer Pharmaceuticals

    Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed t
    '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
    2. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
    3. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
    4. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
    5. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
    6. Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
    7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
    8. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
    9. Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level
    10. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
    11. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/17/2014)... , Sept. 17, 2014 RXi Pharmaceuticals ... company focused on discovering, developing and commercializing innovative ... technologies, today announced that it has been granted a ... Office on its unique delivery system for delivering ... phagocytic cells for the treatment of diseases with ...
    (Date:9/17/2014)... 17, 2014 First ... from a truly novel class of anti-infective ... Biopharma, a biopharmaceutical company developing a truly ... it has secured £4.0m ($6.4m) to advance ... against a range of Gram-positive infections including  ...
    (Date:9/16/2014)... “Nature has developed, very cleverly, some lessons ... in optical design,” said Joseph Shaw, director of the ... explore surfaces and structures at the nanoscale, we’ll discover ... San Diego in August during a conference called “ ... by Shaw and Rongguang Liang of the University of ...
    (Date:9/16/2014)... WASHINGTON, D.C., September 16, 2014 --The emerging field ... portable to the next level, enabling the construction ... highly efficient devices, individual molecules would take on ... and transistors. , A team of researchers from ... potential candidate for use in small-scale electronics: a ...
    Breaking Biology Technology:RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5The future face of molecular electronics 2
    ... Champions Oncology Inc. (OTC: CSBR) announced today that ... certification from the Maryland Department of Health and Mental ... company to conduct medical laboratory tests. ... approval is a significant milestone for our Company. This ...
    ... 2012 The " Anesthesia Drugs Market ... analyzes and studies the U.S. market for intravenous anesthesia drugs with special ... export & import system for controlled substances in U.S. and U.S. market ... TOC of   " Anesthesia Drugs Market ...
    ... was able to reach for and sip from a drink on ... by using her thoughts to direct a robotic arm. ... is evaluating the safety and feasibility of an investigational device called ... brain-computer interface (BCI) intended to put robotics and other assistive technology ...
    Cached Biology Technology:Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities 2Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities 3Anesthesia Drugs Market in U.S. worth $7 Billion by 2015: MarketsandMarkets 2Anesthesia Drugs Market in U.S. worth $7 Billion by 2015: MarketsandMarkets 3Paralyzed individuals use thought-controlled robotic arm to reach and grasp 2Paralyzed individuals use thought-controlled robotic arm to reach and grasp 3Paralyzed individuals use thought-controlled robotic arm to reach and grasp 4Paralyzed individuals use thought-controlled robotic arm to reach and grasp 5
    (Date:9/16/2014)... same viruses that make us sick can take up ... a sneeze, cough or other troublesome symptom, according to ... St. Louis. , On average, healthy individuals carry ... researchers report online in BioMed Central Biology . ... the diversity of viruses in healthy people. , ...
    (Date:9/16/2014)... the dinosaurs 66 million years ago decimated the evergreens ... than their deciduous peers, according to a study led ... journal PLOS Biology . , Applying biomechanical ... leaves of angiosperms flowering plants excluding conifers ... of a diverse plant community thriving during a 2.2 ...
    (Date:9/16/2014)... new school year, a new football season and another ... September, SpaceX,s Dragon spacecraft is scheduled to blast off ... part of the company,s fourth contracted mission to the ... third suite of research investigations sponsored by the Center ... the role of managing the U.S. National Laboratory on ...
    Breaking Biology News(10 mins):Healthy humans make nice homes for viruses 2Healthy humans make nice homes for viruses 3Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4CASIS research set for launch aboard SpaceX mission to space station 2CASIS research set for launch aboard SpaceX mission to space station 3
    ... Conn.A team led by Yale University researchers has used ... the first time. Their findings, which appear December 13 ... , could dramatically simplify the way physicians test for ... The teamled by Mark Reed, Yale,s Harold Hodgkinson Professor ...
    ... fruit increases, growers are being challenged to bring ... their bottom line, orchard owners are experimenting with ... reducing labor costs. Hand thinning, a common ... fruit, is among the most labor-intensive of orchard ...
    ... degrade the diverse types of defective proteins and thus protect ... Professor Thomas Sommer, Professor Udo Heinemann and Dr. Ernst Jarosch ... Germany, have now found a crucial piece in this puzzle. ... the quality control of proteins, they discovered a scaffold regulating ...
    Cached Biology News:Scientists use nanosensors for first time to measure cancer biomarkers in blood 2Horizontal string trimmer reduces labor costs, increases peach size 2MDC researchers identify a scaffold regulating protein disposal 2
    ... is a personal desktop unit ideal for use ... , Rotation speed set at 12 rpm ... C , Bottle capacity of four 35 ... ml conical ,plastic bottles , Consistent, repeatable ...
    ... The SC250 Express is the latest edition ... SC250 Express has an extra large diameter ... The digital display panel allows precise setting ... Large chamber for handling large quantities and ...
    ... a no-frills, basic SpeedVac concentrator designed for ... this unit still features a standard Teflon ... of time and heat. It is designed ... a wide variety of different rotors for ...
    ... RC Maxi MB (for aqueous, other low ... evaporator systems respond to specific applications of ... safe concentration of heat-labile samples. The RC ... of cold traps and a wide selection ...
    Biology Products: